

HMA WGEO – Rapid Alert Form

Counterfeit or illegal product found in the illegal supply chain

Reference:		
Date:	Time:	Initials:
Please complete sections 1 to 5 providing as much information as possible.		
1. REPORTING PERSON		
Name:	Position:	
Organisation: Danish Health and Medicines Authority		
Address: 1 Axel Heides Gade, 2300 Copenhagen S, Denmark		
Telephone No: (Direct):	Ext:	
e-mail address:		
2. PRODUCT DETAILS		
Product name: CoB9 Dietary Supplement		
Manufacturer: (According to package) Manufactured under License By Sukrit 55 co., Ltd. 78/6 Moo 1, Mueang District, Samut Sakhon 74000 / Distributed by Beaute medica Co., Ltd. 39/23 Floor3, Phokæw Rd., Nawamin, Beaugkhum 10240 ine. 02-9484990, 081-9666154, 089-9666554 E-mail cob9.official@gmail.com www.cob9official.com.		
Supplier:		
Legal status: Banned <input type="checkbox"/> Counterfeit <input checked="" type="checkbox"/> Unlicensed <input type="checkbox"/> Stolen <input type="checkbox"/>		
Dosage form: Capsule		
Strength:		
Batch / lot no: 130214 Is batch number genuine: Yes <input type="checkbox"/> No <input type="checkbox"/>		
If yes to the above, advise batch destination country:		
Expiry date: 150216		
Language of packaging: English/other		
Date of discovery: Package seized at CPH Airport on 1 May 2014.		
Details of discovery: Product seized at CPH Airport by Danish Customs and handed over to the DMA for further evaluation. Analysis concluded on 22 July 2014.		
Analysed: YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>		

If yes, result of analysis: **Sibutramine was identified in the sample at a level of approximately 3 mg per capsule.**

3. DISTRIBUTION METHOD

Internet: YES / NO Presumed Internet

Internet: _____ Non internet, advise full details:

URL:

Website address:

Other details:

Currency of payment:

Has product reached patients/consumers? **Unknown**

4. RISK TO PUBLIC HEALTH

Adverse reactions: YES / NO

If yes, please advise details: **Approved medicines containing Sibutramine were withdrawn from the market in January 2010 due to serious side effects of Sibutramine.**

Medical assessment details:

5. NEED FOR PUBLICITY

Are you making a public statement? YES / NO

Are you issuing a press release? YES / NO

Are you recalling product? YES / NO

If yes to any of the above, when do you intend to take action?

6. DISSEMINATION

Are you content for this Rapid Alert to be shared outside WGEO membership? YES / NO (please see below)

If yes, please specify which of the below you are content for this to be shared with (you may tick more than 1 box)

Law Enforcement Industry Security Trade Associations

Traders Other Please specify _____

7. PHOTOGRAPH

If possible, please attach a photograph of the product.

